MedElevator Войти в исследования
← Поиск публикаций

DOI 10.21037/cco-25-50

Медицинская библиотека · Chinese clinical oncology · 2025

Neoadjuvant chemoimmunotherapy or chemoradiotherapy in stage III non-small cell lung cancer: crossing the Rubicon?

Redondo-González Juan Carlos, Posado-Domínguez Luis, Corvo-Félix Laura, Miramontes-González José Pablo, Fonseca-Sánchez Emilio, Del Barco-Morillo Edel, Olivares-Hernández Alejandro

СтатьяОбзорПеревод пока не подготовлен

Аннотация

BACKGROUND AND

OBJECTIVE

Lung cancer is the most frequently diagnosed cancer and the leading cause of cancer-related mortality worldwide. Non-small cell lung cancer (NSCLC) represents 80-85% of cases, with 20-35% diagnosed at stage III. Stage III NSCLC is highly heterogeneous, encompassing both resectable and unresectable disease. The aim of this article is to review current evidence on the treatment of stage III NSCLC, with a focus on neoadjuvant chemoimmunotherapy (CT-IO) vs. the standard of chemoradiotherapy (CT/RT) followed by consolidation immunotherapy.

METHODS

The narrative review was conducted and carried out using clinical trials and studies included were found through searching several databases: PubMed, Cochrane, Science Direct, EMBASE, and the clinical trial registry (www.clinicaltrials.gov).

KEY CONTENT AND FINDINGS: Historically, concurrent CT/RT followed by 1 year of durvalumab has been the standard for unresectable stage III disease, as demonstrated in the PACIFIC trial. The introduction of CT-IO neoadjuvant regimens has shown improved outcomes in stage IIIA and IIIB disease, particularly in terms of pathological complete response (pCR), event-free survival (EFS), and overall survival (OS). Clinical trial heterogeneity regarding tumor-node-metastasis (TNM) staging, patient selection, and adjuvant therapy duration limits direct comparisons. However, emerging data suggest that CT-IO could become a new standard for stage IIIA and selected IIIB/IIIC patients. Neoadjuvant CT-IO represents a significant shift in the treatment paradigm of stage III NSCLC, offering personalized and potentially more effective therapeutic options.

CONCLUSIONS

While CT/RT remains essential for certain subsets, particularly T4 or unresectable tumors, CT-IO should be strongly considered for most patients with stage IIIA and IIIB NSCLC.

Для цитирования: Redondo-González Juan Carlos, Posado-Domínguez Luis, Corvo-Félix Laura, Miramontes-González José Pablo, Fonseca-Sánchez Emilio, Del Barco-Morillo Edel, Olivares-Hernández Alejandro. Neoadjuvant chemoimmunotherapy or chemoradiotherapy in stage III non-small cell lung cancer: crossing the Rubicon?. Chinese clinical oncology. 2025. DOI: 10.21037/cco-25-50.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.